Beating EPS estimates could be seen positively by investors, indicating better-than-expected profitability. However, missing sales estimates significantly could raise concerns about growth and demand for C4 Therapeutics' products, potentially offsetting the positive EPS impact. The mixed results lead to a neutral short-term price direction expectation.